Ten63 Therapeutics Elects Steve Hall as Independent Director
DURHAM, N.C., Aug. 3, 2023 /PRNewswire/ -- Ten63 announces the election of Steve Hall to its board of directors. Hall, who retired as a Partner at LV Management Group (Lilly Ventures) after 12 years, brings a distinguished career in drug discovery and venture capital to Ten63. Among his many successful investments, Hall was a Series A investor in Kymera and Nimbus, companies that, similar to the goals of Ten63, seek to bring to clinical proof of concept small molecule drugs discovered through new modalities.
- DURHAM, N.C., Aug. 3, 2023 /PRNewswire/ -- Ten63 announces the election of Steve Hall to its board of directors.
- Hall, who retired as a Partner at LV Management Group (Lilly Ventures) after 12 years, brings a distinguished career in drug discovery and venture capital to Ten63.
- In addition, Steve served as a board director of many successful companies during similar phases of growth in which we find ourselves.
- As a venture investor, Hall led investments in, and served on the boards of, nine drug discovery companies, including: Cavion, Cerulean Therapeutics, Esanex, FORMA Therapeutics, Hydra Biosciences, Kymera Therapeutics, Lysosomal Therapeutics, Nimbus Therapeutics, and Numerate.